Model‐based comparisons of post‐treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.16197
Abstract: Omalizumab is an anti‐immunoglobulin E (IgE) monoclonal antibody that was first approved by the United States (US) Food and Drug Administration (FDA) for the treatment of allergic asthma in 2003. The pivotal trials supporting the… read more here.
Keywords: united states; asthma dosing; free ige; omalizumab ... See more keywords